NCT04534439 - Safety, Tolerability and Renal Effects of APX-115 in Subjects With Type 2 Diabetes and Nephropathy | Biotech Hunter

Enrollment

140

Participants

Timeline

Start Date

August 24, 2020

Primary Completion Date

July 26, 2021

Study Completion Date

August 23, 2021

Conditions

Diabetic NephropathiesDiabetes Mellitus, Type 2Nephropathy, Diabetic

Interventions

DRUG

APX-115

oral administration of APX-115 400mg capsule once daily for 12 weeks

DRUG

Placebo

oral administration of APX-115-matching placebo 400mg capsule once daily for 12 weeks

Trial Locations (16)

Unknown

Pleven, Pleven

Sveta Karidad, Plovdiv

Diagnostic-consultative centre I, Sliven

Hadzhi Dimitar, Sofia

HERA, Sofia

Medical center - Sveti Dimitar, Sofia

Sirtuin, Sofia

Sveta, Sofia

Hristo Botev, Vratsa

Sveti Panteleymon Yambol, Yambol

Nefromed s.r.o, Prague

Drug Research Center, Balatonfüred

UNO MEDICAL Trials Kft., Budapest

Mint House Private Medical Center, Székesfehérvár

Bezanijska Kosa, Belgrade

Clinical Centre of Serbia, clinic for endocrinology, diabetes and metabolism diseases, department for obesity, metabolic and reproductive disorders, Belgrade